DMAC DiaMedica Therapeutics Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401040 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-26.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-100.2%
ROA-86.3%
ROIC (approx.)-94.2%
Asset turnover—
Leverage & solvency
Liabilities / assets20.7%
Debt / equity0.00x
Current ratio4.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $9.24M | $8.15M | $7.99M | $6.70M | $6.44M | $5.82M | $5.66M | $6.47M |
| SG&A expense | $2.38M | $2.35M | $2.50M | $2.51M | $2.60M | $2.19M | $2.49M | $1.95M |
| Operating income | -$11.62M | -$10.50M | -$10.48M | -$9.21M | -$9.03M | -$8.01M | -$8.14M | -$8.42M |
| Pretax income | -$11.30M | -$10.13M | -$10.04M | -$8.73M | -$8.61M | -$7.69M | -$7.70M | -$7.89M |
| Income tax | $8,000 | $7,000 | $7,000 | $10,000 | $6,000 | $6,000 | $6,000 | $9,000 |
| Net income | -$11.31M | -$10.14M | -$10.04M | -$8.74M | -$8.62M | -$7.70M | -$7.71M | -$7.90M |
| EBITDA | -$11.61M | -$10.49M | -$10.47M | -$9.20M | -$9.02M | -$8.00M | -$8.13M | -$8.41M |
| EPS (basic) | -0.21 | -0.19 | -0.19 | — | -0.17 | -0.18 | -0.18 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.80M | $5.13M | $4.87M | $15.65M | $3.33M | $4.11M | $2.59M | $3.02M |
| Short-term investments | $28.11M | $38.38M | $46.46M | $44.24M | $51.99M | $25.93M | $33.73M | $41.12M |
| Receivables | $176,000 | $244,000 | $301,000 | $258,000 | $260,000 | $161,000 | $253,000 | $236,000 |
| Current assets | $35.49M | $44.31M | $52.36M | $60.63M | $56.22M | $31.08M | $37.42M | $44.61M |
| PP&E, net | $131,000 | $133,000 | $142,000 | $145,000 | $150,000 | $152,000 | $149,000 | $148,000 |
| Total assets | $36.15M | $45.00M | $53.08M | $61.37M | $57.05M | $31.47M | $38.83M | $46.34M |
| Current liabilities | $7.45M | $6.59M | $5.75M | $5.13M | $5.27M | $4.12M | $4.67M | $5.39M |
| Total liabilities | $7.49M | $6.66M | $5.84M | $5.26M | $5.42M | $4.30M | $4.88M | $5.63M |
| Shareholders' equity | $28.66M | $38.34M | $47.23M | $56.11M | $51.62M | $27.17M | $33.95M | $40.72M |
| Shares outstanding | 53.96M | 53.93M | 53.88M | 53.74M | 52.08M | 43.07M | 42.86M | 42.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.83M | -$8.11M | -$9.08M | -$7.76M | -$6.55M | -$7.60M | -$7.15M | -$6.43M |
| Capital expenditure | $10,000 | $3,000 | $8,000 | $6,000 | $16,000 | $6,000 | $12,000 | $7,000 |
| Free cash flow | -$8.84M | -$8.12M | -$9.09M | -$7.77M | -$6.57M | -$7.60M | -$7.16M | -$6.44M |
| Investing cash flow | $10.39M | $8.24M | -$2.11M | $8.00M | -$25.77M | $8.96M | $6.62M | $5.21M |
| Financing cash flow | $114,000 | $132,000 | $417,000 | $12.09M | $31.53M | $161,000 | $91,000 | $120,000 |
| Depreciation & amortization | $12,000 | $12,000 | $11,000 | $11,000 | $18,000 | $3,000 | $11,000 | $11,000 |
| Stock-based compensation | $1.53M | $1.12M | $822,000 | $1.19M | $1.02M | $771,000 | $867,000 | $589,000 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.